Drug Profile

KRRO 110

Alternative Names: KRRO-110

Latest Information Update: 27 Nov 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Korro Bio
Class Oligonucleotides
Mechanism of Action Alpha 1-antitrypsin modulators; RNA modulators

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Alpha 1-antitrypsin deficiency
New Molecular Entity Yes

Highest Development Phases

Phase I/II Alpha 1-antitrypsin deficiency

Most Recent Events

19 Nov 2025 KRRO 110 receives Fast Track designation for Alpha 1-antitrypsin deficiency [IV,Infusion] in USA, prior to November 2025
12 Nov 2025 Adverse events, pharmacokinetics and pharmacokinetics data from the phase I/IIa REWRITE trial in Alpha-1 antitrypsin deficiency released by Korro Bio
21 Jul 2025 KRRO 110 receives Orphan Drug status for Alpha 1-antitrypsin deficiency in European Union

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com